PREPIC 2 : Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption (PREPIC2)

PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study

The purpose of this study is to assess efficacy and safety of optional vena cava filter implanted 3 months in prevention of recurrent pulmonary embolism in patients presenting with acute pulmonary embolism associated with thrombotic risk factors

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Pulmonary embolism is a common pathology, which could be fatal (about 10 000 death/year in France). It mainly originates from a deep vein thrombosis. In order to reduce mortality, prevention of new or recurrent PE is a major therapeutic aim. Only one randomised trial (PREPIC) assessed the interest of a vena cava filter in patients treated by anticoagulant treatment for a deep vein thrombosis (DVT). Results show a significant 50 % reduction of the embolic risk with the filter. This benefit occurs from the first days, but are counterbalanced by a long-term increasing risk of recurrent DVT. The filter appears promising in patients with a high risk of PE, for exemple the elderly, presenting with a thromboembolic history, cancer, heart failure or respiratory insufficiency, or a recent PE. Moreover, retrievable filters, which may be either left in place permanently or retrieved after some days or weeks, could limit the filter thrombosis risk.

The aim of PREPIC 2 study is to assess, in a multicenter randomised trial, efficacy and safety of a retrievable vena cava filter implanted 3 months versus no filter in 400 patients treated with anticoagulant drugs for a symptomatic PE associated with at least one thrombotic risk factor. A clinical follow-up will be performed at 6 months. The primary outcome is the incidence of recurrent PE at 3 months, including symptomatic and fatal PE. It will be adjudicated by an independent committee, blinded to patients' allocation.

This study will assess the benefit risk ratio of the retrievable filter for the prevention of recurrent PE, without increasing the thrombotic risk and the disadvantage due to post thrombotic syndrome.

Study Type

Interventional

Enrollment (Actual)

399

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Amiens, France, 80080
        • Service de Médecine Vasculaire, CHU Amiens
      • Angers, France, 49100
        • Service d'Accueil des Urgences, CHU d'Angers
      • Besançon, France, 25000
        • Service de Cardiologie, CHU de Besançon
      • Bordeaux, France, 33000
        • CHU de Bordeaux
      • Brest, France, 29200
        • Département de Medecine Interne et Pneumologie, CHU de Brest
      • Clamart, France, 92140
        • Service de Pneumologie, Hôpital Antoine Beclere
      • Clermont Ferrand, France, 63000
        • Service d'Accueil des Urgences, CHU de Clermont Ferrand
      • Dijon, France, 21000
        • CHU de Dijon
      • Firminy, France, 42700
        • Service des Urgences, CHG de Firminy
      • Grenoble, France, 38000
        • Unité de Médecine Vasculaire, CHU de Grenoble
      • Lille, France, 59000
        • Service d'Urgences Soins Intensifs cardiologiques, CHU de Lille
      • Lyon, France, 69437
        • Hôpital Edouard Herriot
      • Montpellier, France, 34295
        • Service de Medecine Interne et Maladies Vasculaires, CHU de Montpellier
      • Nancy, France, 54000
        • Service de Medecine Interne et Vasculaire, CHU de Nancy
      • Nice, France, 06000
        • Service de Cardiologie, CHU de Nice
      • Paris, France, 75015
        • Département de Pneumologie, Hôpital Européen Georges Pompidou, AP HP
      • Saint-Etienne, France, 42055
        • Service d'Urgences et de Réanimation Medicale, CHU de Saint-Etienne
      • Saint-Etienne, France, 42055
        • Service de Medecine et Therapeutique - CHU de Saint-Etienne
      • Toulon, France, 83056
        • Service de Médecine Vasculaire, CH Toulon
      • Tours, France, 37000
        • Service de Cardiologie, CHU de Tours

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Informed consent
  • Acute symptomatic pulmonary embolism; AND
  • Deep or superficial vein thrombosis; AND
  • At least one of the risk factors below :

    • More than 75 years old
    • Evolutiv cancer (excepting locally cutaneous cancer)
    • Known chronic heart failure treated
    • Chronic respiratory insufficiency treated
    • Bilateral deep vein thrombosis
    • Ilio-cava thrombosis
    • Ischemic stroke > 3 days and < 6 months, with lower limb deficit
    • Cardiac repercussion of pulmonary embolism assessed by echocardiography or increasing troponin I or T, or Brain Natriuretic Peptid or proBNP

Exclusion Criteria:

  • Contrindication to an anticoagulant treatment or recurrent thromboembolic event despite adequate anticoagulation
  • Vena cava filter already inserted
  • Filter insertion impossible due to caval thrombosis
  • More than 72 hours pre-randomized treatment with therapeutic dosage of anticoagulant therapy
  • Non carcinologic surgery within 3 months prior randomization
  • Carcinologic surgery within 10 days prior randomization
  • Hypersensitivity to contrast media
  • Access port in place or programmed within 3 months
  • Woman who are child bearing
  • Life expectancy < 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 1
ALN optional filter
J1 : ALN optional filter M3 : ALN optional filter removed
No Intervention: 2
No ALN optional filter

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
at 3 months, combined criteria including recurrent PE confirmed by objective tests and fatal PE confirmed by autopsy and death which can not be attribuated to a documented cause and for which PE/DVT can't be ruled out
Time Frame: 3 months
3 months

Secondary Outcome Measures

Outcome Measure
Time Frame
recurrent pulmonary embolism, fatal or not, at 6 months (combined criteria including recurrent pulmonary ambolism confirmed by objective tests and fatal PE confirmed by autopsy and death which can not be attribuated to a documented cause and for which P
Time Frame: 6 months
6 months
current or new symptomatic DVT confirmed by objective tests
Time Frame: 6 months
6 months
mecanical complication of filter (migration, tilt, transfixion) and or puncture site hematoma, and/or local or general infection due to filter
Time Frame: 6 months
6 months
filter thrombosis
Time Frame: 6 months
6 months
filter retrieval failure
Time Frame: 6 months
6 months
total death
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2006

Primary Completion (Actual)

November 1, 2012

Study Completion (Actual)

November 1, 2012

Study Registration Dates

First Submitted

April 4, 2007

First Submitted That Met QC Criteria

April 4, 2007

First Posted (Estimate)

April 5, 2007

Study Record Updates

Last Update Posted (Estimate)

November 27, 2012

Last Update Submitted That Met QC Criteria

November 22, 2012

Last Verified

November 1, 2012

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe